Used in pharmaceutical research as a potent and selective inhibitor of phosphodiesterase 10A (PDE10A), this compound is investigated for its potential in treating central nervous system disorders, particularly schizophrenia and other psychiatric conditions involving dysregulation of dopamine signaling. By modulating intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in the brain, it helps regulate neuronal activity in pathways associated with cognition, motivation, and reward. Its ability to cross the blood-brain barrier enhances its utility in neuropharmacology. Preclinical studies focus on its efficacy in improving cognitive and negative symptoms of schizophrenia without inducing motor side effects commonly seen with antipsychotics.